Recommendation MAI-118: Review intramuscular TXA on frontline ambulances
From Manchester Arena Inquiry: Volume 2: Emergency Response, published 3 November 2022.
Recommendation
The Department of Health and Social Care, the Faculty of Pre-Hospital Care, the College of Paramedics and the National Ambulance Resilience Unit should undertake a review into whether frontline ambulances should carry intramuscular tranexamic acid or TXA.
In brief (written by this site)
The Cabinet Office reported in February 2026 that delivery remained in progress, noting that the availability of intramuscular administration had been reinforced within guidelines (Cabinet Office, Feb 2026). It added in February 2026 that trials would be undertaken once the ongoing development of auto injector presentations is complete, and that legislative requirements were being reviewed for wider use by responders (Cabinet Office, Feb 2026). The UK Government had accepted the recommendation in full in November 2025 (Cabinet Office response, Nov 2025).
AI-generated summary of the record on this page, checked by a second model and automatic checks, 26 Sep 2026. The record below is the sources' own words.
Government response
Accepted in full
Delivery
Cabinet Office says in progress (27 February 2026)
Reinforcement of availability of IM administration within guidelines Ongoing development of auto injector presentations, once available trials will be undertaken Legislative requirements being reviewed for wider use by responders
Earlier statement on delivery (1)
Cabinet Office (14 November 2025)
Reinforcement of availability of IM administration within guidelines Ongoing development of auto injector presentations, once available trials will be undertaken Legislative requirements being reviewed for wider use by responders
From: Manchester Arena Inquiry Recommendations Dashboard, original version (data file)
Source
Responsible bodies
Themes and tags
Who has spoken
- UK Government
Response - Cabinet Office
Delivery statement